#HPV 16 & 18 Detection Kit

[pathologylab]

HPV genotypes 16 and 18 cause approximately 70% of cervical cancers and pre-cancerous cervical lesions.

Genes2Me developed a high-quality HPV-Q Real-time PCR kit for the Detection of 14 high-risk genotypes and differentiating 16, 18, and other 12 high-risk in a single tube multiplex assay is effective in detecting the presence of HPV in clinical samples.

Testing with RT-PCR kits is more sensitive than smear microscopy. It is cost-effective making it the preferred global diagnostics solution for the fast and accurate detection of 14 high-risk genotypes.

Genes2Me HPV RTPCR kit has a run time of less than 60 minutes, 99% sensitivity & 100% specificity, and is compatible with all commonly available 4 Plex real-time PCR Instruments.

Contact us to learn more about it. Call now for a demo kit or to place an order. 18001214030

To Know more Visit: https://t2m.io/HPV-RTPCR

[adityarana1687-blog]

Cervical Dysplasia Market Is Expected To Witness Higher Demands Till 2025

The global cervical dysplasia market size is expected to reach USD 890.9 million by 2027, expanding at a CAGR of 7.3%, according to a new report by Grand View Research, Inc. Key drivers of the market include the increasing prevalence of cervical cancer cases, rise in government initiatives, and growing awareness. According to the WHO, cervical cancer is the 4th most frequent disease observed in women across the globe. An estimated 570,000 new cases of the disease were observed during 2018 that represents 6.6% of all cancers in females. Most of the deaths caused due to the disease were observed in middle and low-income countries.

In addition, government and other major players are also undertaking initiatives in order to enhance awareness among women across the globe. For instance, in 2018, WHO launched a Plan of Action for Cervical Cancer Prevention and Control 2018 to 2030. The major goal of this plan is to accelerate progress towards eliminating the disease in the region U.S. by reducing mortality and incidence rates by one-third by 2030.

Also, seven UN agencies that are under the United Nations Task Force on NCDs established a 5-year Joint Program to prevent and control cervical cancer. The program aims at providing technical assistance as well as global leadership to support governments as well as their partners to sustain and build high quality national comprehensive cervical cancer control programs for women. Thus, a rise in initiatives undertaken by the government is expected to upsurge the usage of cervical dysplasia tests in the near future.

Growing initiatives undertaken by major market players is also one of the factors expected to fuel the market growth during the forecast period. For instance, in November 2019, BD announced that the company submitted a premarket approval supplement to the U.S. FDA in order to expand BD Onclarity HPV Assay’s version. The assay detects HPV genotypes 45, 18, and 16. The company seeks approval from the U.S. FDA to include HPV genotypes 51, 31, and 8 additional types to BD Onclarity HPV Assay. Therefore, the rise in product advancements done by major market players is expected to boost market growth.

The rise in the number of product launches is expected to fuel the market growth during the forecast period. For instance, in December 2018, Nurx a telemedicine startup based in California launched an HPV testing kit, which is a direct-to-customer product. The test is free of cost with insurance and facilitates the detections of 14 high-risk HPV genotypes. This initiative encourages women living in rural areas as well as those without insurance with cervical cancer screening tests. Thus, North America is expected to witness exponential growth owing to the rise in initiatives undertaken by startups in the region to increase the adoption of HPV tests across women aged 25 years and above. Therefore, a growing number of initiatives undertaken by new market players are also expected to enhance the diagnosis of cervical cancer.

Request a free sample copy or view report summary: Cervical Dysplasia Market Report

Cervical Dysplasia Market Report Highlights

Diagnostic tests are anticipated to dominate the market during the forecast period owing to the efficacy, flexibility, and cost-effectiveness of the tests

Hospitals held the largest market share in 2019 owing to the availability of technologically advanced diagnostic devices and tests and the presence of various reimbursement policies

In North America, the market is expected to witness exponential growth during the forecast period owing to a rise in the prevalence of cervical cancer, a growing number of awareness and screening campaigns, and the launch of technologically advanced products for the diagnosis of cervical dysplasia.

Cervical Dysplasia Market Segmentation

Grand View Research has segmented the global cervical dysplasia market on the basis of diagnosis type, end-use, and region:

Cervical Dysplasia Diagnosis Type Outlook (Revenue, USD Million, 2016 - 2027)

Diagnostic Tests

Diagnostic Devices

HPV Test

Pap Smear Test

Biopsy Test

Colposcope

Cervical Dysplasia End-use Outlook (Revenue, USD Million, 2016 - 2027)

Hospitals

Diagnostic Centers

Ambulatory Surgical Centers

Cervical Dysplasia Regional Outlook (Revenue, USD Million, 2016 - 2027)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

The U.S.

Canada

The U.K.

Germany

France

Italy

Spain

Russia

Japan

China

India

South Korea

Australia

Singapore

Brazil

Mexico

Argentina

South Africa

Saudi Arabia

UAE

List of Key Players of Cervical Dysplasia Market

Qiagen N.V.

Quest Diagnostics

Abbott Laboratories

Hologic, Inc.

Karl Kaps GmbH & Co. KG

DYSIS Medical Ltd.

CooperSurgical Inc.

Micromedic Technologies Ltd.

OncoHealth Corporation, Inc.

BD and Roche

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

[fitnesshealthyoga-blog]

New Post has been published on https://fitnesshealthyoga.com/hpv-vaccine-to-be-offered-to-boys-in-northern-ireland/

HPV vaccine to be offered to boys in Northern Ireland

Media playback is unsupported on your device

Media captionCancer-preventing vaccine extended to boys

Two new health initiatives are set to be rolled out in the fight against cancer.

Boys aged 12-13 in Northern Ireland are to be offered a vaccine to protect them against Human Papilloma Virus (HPV)-related cancers.

A better bowel cancer detection test is also being introduced.

They are significant announcements for public health as they bring Northern Ireland into line with the rest of the UK.

From September the HPV vaccine will be offered to all boys in year nine at school.

It is hoped the immunisation programme will help reduce diagnoses of HPV-related cancers and save lives.

It has also been decided that the Faecal Immunochemical Test (FIT) will replace the Faecal Occult Blood (FOB) test as the primary screening test for bowel cancer in the Bowel Cancer Screening Programme (BCSP) in Northern Ireland.

This however will not begin until early 2020.

Department of Health permanent secretary Richard Pengelly said health protection clearly benefits the public.

“Both decisions have been under active consideration for some time and can now be made, following confirmation of the department’s budget allocation for this year,” he said.

A very high proportion of all women under 25 have already taken up the opportunity to be vaccinated against the HPV virus since the programme was first introduced in 2008 and the intention is to protect boys through similar uptake rates.

What is the Human Papilloma Virus (HPV)?

Image copyright Getty

HPV is the name given to a common group of viruses; there are more than 100 types of HPV

Many women will be with infected with HPV over the course of their lifetime without any ill-effect

In the vast majority of cases, there will be no symptoms and the infection will clear on its own, but in some cases persistent infection can lead to cervical disease

Some types of HPV are high risk because they are linked to the development of some cancers

Nearly all cervical cancers (99.7%) are caused by infection from a high risk HPV

Many types of HPV affect the mouth, throat or genital area. They’re easy to catch – you can get HPV from sexual contact.

Source: NHS Choices

This extended programme offers the opportunity to make some HPV-related diseases and cancers a thing of the past building on the success of the programme in girls.

The prevalence of the main HPV cancer-causing types 16 and 18 has already been reduced by more than 80%.

Chief Medical Officer, Dr Michael McBride, said: “We can now look forward to a future where we can be even more confident that we will reduce cervical cancer and other HPV related cancers that affect both men and women.

“This is an effective vaccine against a particularly harmful virus. I would encourage all parents to take up this offer and ensure their boys and girls are vaccinated.”

The new FIT bowel screening test will be introduced from early 2020.

While cancer charities welcome the move it had been hoped that it could have been introduced sooner.

Self-testing kit ‘saved my life’

Jeremy Bowen diagnosed with bowel cancer

Evidence has shown there is increased patient acceptability of the FIT screening test and increased uptake of screening will mean even more lives can be saved.

Every year in Northern Ireland there are about 1,100 new cases of bowel cancer, with more than 400 deaths.

The BCSP aims to pick up bowel cancer at an early stage, when treatment can be 90% successful.

What are the symptoms of bowel cancer?

bleeding from your bottom and/or blood in your poo

a persistent and unexplained change in bowel habit

unexplained weight loss

extreme tiredness for no obvious reason

a pain or lump in your tummy

“The existing test for bowel cancer has proved hugely valuable in detecting cancer early and it is therefore essential that people invited to participate in the Northern Ireland Bowel Screening programme from 60-74 continue to complete it,” Dr McBride said.

Extending the HPV vaccination programme to include adolescent boys is based on advice from the Joint Committee of Vaccination and Immunisation (JCVI), an independent panel of experts that provides advice to the four UK Health Departments.

In January 2016, the UK National Screening Committee recommended that quantitative Faecal Immunochemical Test (FIT) should be adopted by the Bowel Cancer Screening Programme (BCSP) as the primary screening test for bowel cancer.

Source link

[sandlerresearch]

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) published on

https://www.sandlerresearch.org/human-papilloma-virus-hpv-tests-in-vitro-diagnostics-global-market-analysis-and-forecast-model-covid-19-market-impact.html

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Summary

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Human Papilloma Virus Tests market for the year 2020 and beyond. Human papillomavirus (HPV) is known as the most common sexually transmitted infection (STI) in the world. Human papillomavirus (HPV) Tests are primarily used to screen for cervical cancer and/or identify women who may be at increased risk of cervical cancer. There are over 150 types of HPV including both high-risk HPV and low-risk HPV. Out of these strains, types HPV-16 and HPV-18 are most commonly associated with development of cervical cancer.

The predominant devices used for HPV detection are Nucleic-acid amplification (NAAT) tests, owing to their high specificity and sensitivity as well as their ability to be adapted for high-throughput testing. Several other HPV DNA detection methods have also been described including in situ hybridization tests, Enzyme Immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA) kits, and next generation sequencing assays.

Factors like favourable government policies, high occurrence rate of HPV infections, and growing cervical cancer screening awareness plans are expected to drive the overall HPV testing market during the forecast period. Genital warts are often caused by non-oncogenic strains of HPV, such as HPV-6 and HPV-11. The HPV tests include NAAT and Other Human Papilloma Virus (HPV) test kits.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are –

Currently marketed Human Papilloma Virus Tests and evolving competitive landscape – – Insightful review of the key industry trends. – Annualized total Human Papilloma Virus Tests market revenue by segment and market outlooks from 2015-2030. – Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights – – Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market. – SWOT analysis for Human Papilloma Virus Tests market. – Competitive dynamics insights and trends provided for Human Papilloma Virus Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape. – Country specific overview of the healthcare system. – Country specific reimbursement policies. – Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Hologic Inc, Roche Diagnostics Corp, Qiagen NV, Biocare Medical LLC, Abbott Laboratories and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for – – CMO executives who must have deep understanding of the Human Papilloma Virus Tests market place to make strategic planning and investment decisions. – Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management. – Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to – – Understand the impact of COVID-19 on Human Papilloma Virus Tests market. – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving Human Papilloma Virus Tests market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Human Papilloma Virus Tests market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Track device sales in the global and country-specific Human Papilloma Virus Tests market from 2015-2030. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

[cancersfakianakis1]

Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination

Abstract

Australia has implemented a high coverage HPV vaccination program but has not to date established the distribution of HPV types that occur in cervical cancers in Australia. This information is important for determining the potential for cervical cancer prevention with both current and broader spectrum HPV vaccines. We analysed 847 cervical cancers diagnosed 2005-2015 in tertiary centres in the three most populous Australian states with resolution of specimens containing multiple HPV types using laser-capture microdissection. Archived FFPE tissue was reviewed by specialist pathologists, sandwich sectioned, and initially whole tissue sections genotyped for HPV. Samples were first genotyped using SPF10-LiPA25. Negative samples were screened with DNA ELISA kit HPV SPF10, followed by genotyping with SPF+ LiPA if ELISA positive. If still negative, samples were tested on a qPCR assay targeting the E6 region of HPV16,18, 45 and 33. Of the 847 cancers (65.1% squamous, 28.7% adenocarcinoma, 4.3% adenosquamous, 2.0% other), 92.9% had HPV detected. Of the HPV positive cancers, 607/787 (77.1%) contained HPV16 or 18, 125/787 (15.9%) contained HPV31/33/45/52 or 58, and 55 (7.0%) another HPV type. There was a strong correlation between HPV type and age, with younger women most likely to have HPV16/18 detected and least likely HPV negative. Our findings indicate that cervical cancers diagnosed in Australia more frequently contain HPV16/18 than in international series. This could be due to cervical screening in Australia increasing the proportion of adenocarcinomas, in which types 18 and 16 more strongly predominate, due to prevention of squamous cancers. This article is protected by copyright. All rights reserved.

http://ift.tt/2sEzPGa

[yogesh-rane-me]

HPV Testing                   

    Scope of the Report: 

1)    About this Report

HPV refers to a group of more than 200 related viruses commonly causing infections that do not have any symptoms. Among these, more than 40 types of HPV cause highly contagious diseases that are transmitted through direct sexual contact, infecting both male and female genitals. The other types of HPV cause non-genital warts that are not sexually transmitted. Though most HPV infections are harmless and heal on their own, certain high-risk types of genital HPV can be persistent and cause cervical, penile, anal, vaginal, and oropharyngeal cancers. Many individuals undergo regular HPV tests as a preventive measure. HPV tests help detect the viral genetic material in a cell sample taken from the cervix.

2)     Analysis of this report

Technavio's analysts forecast the global HPV testing market to grow at a CAGR of 16.17% over the period 2014-2019. 

3)     Covered in this Report This report covers the present and future scenarios of the global HPV testing market for the period 2015-2019. To calculate the market size, Technavio uses revenue generated from the sales of HPV testing kits and detection systems. The report includes the segmentation of the market based on the following three regions: the Americas, APAC, and EMEA. Technavio's report, Global HPV Testing Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. . 

Request For Sample Report http://ift.tt/2onCy4U

Key Regions • Americas • APAC • EMEA Key Vendors • Abbott Diagnostics • Hologic • Qiagen • Roche Diagnostics Other Prominent Vendor • Arbor Vita • Becton, Dickinson and Company • Cepheid • Delphi Bioscience • DiaCarta • Diasorin • Fujirebio • Genera Biosystems • IncellDx • OralDNA Labs • Quest Diagnostics • Seegene • Trovagene • Ventana Medical Systems Market Driver • Increased Incidence of HPV • For a full, detailed list, view our report Market Challenge • Lack of Public Awareness • For a full, detailed list, view our report Market Trend • Co-testing with HPV and Pap Tests • For a full, detailed list, view our report Key Questions Answered in this Report • What will the market size be in 2019 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors?

Complete Report: http://ift.tt/2oEg5MN

Table of Contents  01 Executive Summary 2 List of Abbreviations 3 Scope of the Report     03.1 Market Overview     03.2 Product Offerings 04. Market Research Methodology     04.1 Market Research Process     04.2 Research Methodology 05. Introduction 06. Market Landscape     06.1 Market Overview     06.2 Market Size and Forecast     06.3 HPV Testing Market in US       06.3.1 Market Size and Forecast     06.4 Five Forces Analysis 07. HPV: An Overview     07.1 HPV Types     07.2 HPV and Cervical Cancer       07.2.1 Incidence and Prevalence       07.2.2 Symptoms       07.2.3 Diagnosis 08. Reimbursement and Coverage: An Overview 09. Geographical Segmentation     09.1 HPV Testing Market in Americas       09.1.1 Market Size and Forecast     09.2 HPV Testing Market in EMEA       09.2.1 Market Size and Forecast     09.3 HPV Testing Market in APAC       09.3.1 Market Size and Forecast 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and Their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and Their Impact 17. Vendor Landscape     17.1 Competitive Scenario       17.1.1 Key News     17.2 Market Share Analysis 2014     17.3 Other Prominent Vendors 18. Key Vendor Analysis     18.1 Abbott Diagnostics       18.1.1 Key Facts       18.1.2 Business Overview       18.1.3 Geographical Presence       18.1.4 SWOT Analysis     18.2 Hologic       18.2.1 Key Facts       18.2.2 Business Overview       18.2.3 Business Segmentation by Revenue 2013       18.2.4 Business Segmentation by Revenue 2012 and 2013       18.2.5 Sales by Geography       18.2.6 Business Strategy       18.2.7 Key Developments       18.2.8 SWOT Analysis     18.3 Qiagen       18.3.1 Key Facts       18.3.2 Business Overview       18.3.3 Product Segmentation by Revenue 2013       18.3.4 Product Segmentation by Revenue 2012 and 2013       18.3.5 Geographical Segmentation by Revenue 2013       18.3.6 Business Strategy       18.3.7 Recent Developments       18.3.8 SWOT Analysis     18.4 Roche Diagnostics       18.4.1 Key Facts       18.4.2 Business Overview       18.4.3 Business Segmentation by Revenue 2014       18.4.4 Business Segmentation by Revenue 2013 and 2014       18.4.5 Geographical Segmentation by Revenue 2014       18.4.6 Business Strategy       18.4.7 Recent Developments       18.4.8 SWOT Analysis 19. Other Reports in This Series

Continued……………

Visit to our official website on Linkedin@ https://goo.gl/CQPn5j

Continued………………….

Buy This Report@  http://ift.tt/2onFYo5  

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

http://ift.tt/1L5gkbE

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)